Publications by authors named "David Rubitski"

Claim this Profile
I
In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformation.
Luping Qiu, Steven W Kumpf, Elias M Oziolor, Mark Sheehan, James E Finley, David M Rubitski

Toxicol Appl Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison and cross-validation of long-read and short-read target-enrichment sequencing methods to assess AAV vector integration into host genome.
Mark Sheehan, Steven W Kumpf, Jessie Qian, David M Rubitski, Elias Oziolor

Mol Ther Methods Clin Dev· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs.
Elias M Oziolor, Steven W Kumpf, Jessie Qian, Mark Gosink, Mark Sheehan, David M Rubitski

Mol Ther Methods Clin Dev· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.
Romain Rouet, Benjamin A Thuma, Marc D Roy, Nathanael G Lintner, David M Rubitski

J Am Chem Soc· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Phosphorylation Consensus Sequences and Endogenous Neuronal Substrates of the Psychiatric Risk Kinase TNIK.
Qi Wang, Stephen P Amato, David M Rubitski, Matthew M Hayward, Bethany L Kormos

J Pharmacol Exp Ther· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior.
Travis T Wager, Ramalakshmi Y Chandrasekaran, Jenifer Bradley, David Rubitski, Helen Berke

ACS Chem Neurosci· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.
Michael A Brodney, David E Johnson, Aarti Sawant-Basak, Karen J Coffman, Elena M Drummond, David M Rubitski

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations.
David E Johnson, Elena Drummond, Sarah Grimwood, Aarti Sawant-Basak, Emily Miller, David M Rubitski

J Pharmacol Exp Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).
Travis T Wager, Betty A Pettersen, Anne W Schmidt, Douglas K Spracklin, Scot Mente, David M Rubitski

J Med Chem· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period.
Kevin M Walton, Katherine Fisher, David Rubitski, Michael Marconi, Qing-Jun Meng

J Pharmacol Exp Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis